The Evidence for Populationwide Reduction in Sodium Intake: Why All the Fuss?
|
|
|
- Harriet Reeves
- 5 years ago
- Views:
Transcription
1 The Evidence for Populationwide Reduction in Sodium Intake: Why All the Fuss? CIA-Harvard Menus of Change National Leadership Summit June 10, 2014 Cambridge, MA General Session IV Lawrence J Appel, MD, MPH C. David Molina, Professor of Medicine Director, Welch Center for Prevention, Epidemiology and Clinical Research Johns Hopkins University School of Medicine The Johns Hopkins University
2 Research Disclosure McCormick Science Foundation
3 Magnitude of the BP Epidemic 54% of strokes and 47% of coronary heart disease events attributed to elevated BP 1 26% of adults worldwide (971 million) have hypertension 2 Lifetime risk 3 of developing hypertension is 90% 1 Lawes CM Lancet 2008;371: Kearney Lancet 2005;305:217 3 Vasan JAMA 2002; 287:1003
4 Big Picture: Worldwide, Elevated BP is the Leading Cause of Preventable Deaths Global health risks: WHO, 12/09
5 Systolic Blood Pressure As Sodium Intake Is Reduced, So is Blood Pressure 8.9 mmhg Typical Diet Optimal diet approach to -6.7* p<.0001 lower BP combines sodium -3.0 P<.0001 reduction and improved diet DASH Diet Sacks, NEJM ,500 2,400 3,300 Sodium Level: mg/d per day *P=0.03 for non-linearity, -2.1 vs -4.6 mmhg
6 Effects of Na Reduction on CVD Events
7 Sodium Reduction Lowers CVD Risk: Meta-Analysis of Trials Events Na/Cntl Trial TOHP I 17 / 32 TOHP II 71 / 80 Morgan 6 / 5 TONE 36 / 46 Total 130 / 163 He FJ, MacGregor GA. Lancet. 2011;378:
8 Range of Estimated Mean Effects from 4% Na Reduction/Year for 10 Years: Life-years Added and Deaths Prevented over 10 Years Low Estimate High Estimate Person-years of life added 919,000 1,817,000 Total deaths 274, ,000 CHD Deaths 145, ,000 Stroke Deaths 30,000 83,000 Major CVD deaths 192, ,000 Coxson, HTN 2013;61:564-70
9
10 Why the fuss about sodium? Scientific issues specific to sodium Methodologic landmines Challenges of measuring sodium Interpretation of low diet and low urinary sodium excretion High cost of high quality sodium research in humans Other scientific issues, not specific to sodium Interpretation of unexpected j-shaped relationships in observational studies Implications of non-bp effects of BP reducing therapies
11 Why the fuss about sodium? Commercial interests Cheap ingredient, increases profit Role of government Evidence to guide policy Role of surrogate outcomes Level of evidence for prevention policy when clinical trials with hard outcomes cannot be done
12 Methodological Issues
13 Is Sodium Reduction Harmful? Three Lines of Evidence Adverse effects on biomarkers Plasma renin activity, sympathetic nervous system activity, glycemia, lipid levels Epidemiologic studies with inverse or j- shaped relationship Heart failure trials from a single center in Palermo, Italy
14 No Effect of Reducing Sodium Intake on LDL Cholesterol Typical Diet LDL-C mmol/l P= P=0.9 DASH Diet Harsha, Hypertension 2004;43;393 1,500 2,400 3,300 Sodium Level: mg/d per day
15
16 Major Methodological Challenges in Observational Studies that Relate Sodium Intake to CVD Errors with Greatest Potential to Alter Direction of Association Systematic error in sodium assessment Reverse causality Errors with Some Potential to Alter Direction of Association Residual confounding Imbalance across groups Low follow-up rate 26 studies with 31 independent samples Errors with Potential to Lead to a False Null Random error in sodium assessment On average, 2.5 issues/study Insufficient power
17 Measurement of Na Intake Optimal Multiple, high quality 24 hour urine collections Suboptimal 24 hour urine collected with limited or no attention to quality control Spot, overnight or timed urines 24 hour dietary recalls Food frequency questionnaire
18 Hazard Ratio (HR) Case of Systematic Error Leading to Bias: Increased CVD Mortality in Persons with Lowest Na (by Quartile of Na Intake in mg/d) P=0.03 Q1 vs Q st 2nd 3rd 4th 1 Cohen, JGIM 2008;23: Na Quartile of based on mg of Na/d
19 Evidence of Contamination in a Cohort Study 1 (NHANESIII) Reporting Increased Mortality in Persons with Low Sodium Intake on 24Hr Dietary Recall Quartile of Sodium Intake: 1 st (Lowest) 2nd 3rd 4 th (Highest) Na (mg/d) 1,501 2,483 3,441 5,497 1 Cohen, JGIM 2008;23:
20 Evidence of Contamination in a Cohort Study 1 (NHANESIII) Reporting Increased Mortality in Persons with Low Sodium Intake on 24Hr Dietary Recall Quartile of Sodium Intake: 1 st (Lowest) 2nd 3rd 4 th (Highest) Na (mg/d) 1,501 2,483 3,441 5,497 Energy Intake (kcal) 1,282 1,762 2,152 2,938 1 Cohen, JGIM 2008;23:
21 Evidence of Contamination Evidence in a Cohort of Massive Study 1 (NHANESIII) Reporting Underreporting Increased Mortality of Calorie in Persons Intake with Low Sodium Intake Leading on 24Hr to Systematic Dietary Recall Error in Estimate or Sodium Intake Quartile of Sodium Intake: 1 st (Lowest) 2nd 3rd 4 th (Highest) Na (mg/d) 1,501 2,483 3,441 5,497 Energy Intake (kcal) 1,282 1,762 2,152 2,938 BMI (kg/m 2 ) Cohen, JGIM 2008;23:
22 J-Shaped Relationship of Total Mortality with Urine Sodium Excretion in Patients with Type 1 Diabetes Extremely low levels are most likely the result of extreme undercollection Thomas, Diabetes Care 2011: 861-6
23 Example of Low Sodium Excretion Related to Under-collection 78 year old women, screened for a trial No special diet 172 pounds, 5 2, BMI 31 kg/m 2 Two 24 hour urine collections required Detailed instructions provided Urine Lab Range 1st 2nd Sodium (mmol/24hr) Volume (ml/24hr) Creatinine (g/24 hr).63 to
24 Unanticipated J-Shaped Relationship: An Investigation
25 All Cause Mortality in Persons with Incident Diabetes (All Participants) Tobias, D. K., et al. (2014). "Body-mass index and mortality among adults with incident type 2 diabetes." N Engl J Med 370(3):
26 All Cause Mortality in Persons with Incident Diabetes (Excluding Early Deaths) Tobias, D. K., et al. (2014). "Body-mass index and mortality among adults with incident type 2 diabetes." N Engl J Med 370(3):
27 All Cause Mortality in Persons with Incident Diabetes (Just Never Smokers) Tobias, D. K., et al. (2014). "Body-mass index and mortality among adults with incident type 2 diabetes." N Engl J Med 370(3):
28 All Cause Mortality in Persons with Incident Diabetes (Just Never Smokers, Excluding Early Deaths) Tobias, D. K., et al. (2014). "Body-mass index and mortality among adults with incident type 2 diabetes." N Engl J Med 370(3):
29 TOHP Phase 3: Observational Study with No Evidence of Biases Leading to Systematic Error
30 Direct, Progressive Relationship of CVD with Urinary Sodium Excretion* in 2,275 Individuals with Prehypertension Cook, Circ 2014:129:981 *Based on 24 hr urine collections (median = 5)
31 Heart Failure Trials: The adverse impact of bad science on public policy
32 Effects of Lower (80 mmol/d) vs Usual (120 mmol/d) Sodium on Outcomes in Patients with Heart Failure Readmissions Readmissions or Death Paterna, Clinical Science (2008) 114,
33 Peculiarities of 6 Heart FailureTrials o Massive concurrent therapy o 100% High dose lasix ( mg/d) o 100% ACEI (Captopril mg/d) o ~80% Spironolactone (25mg/d) o Details of dietary intervention unclear o? Just advice o Funding source mentioned in 1/6 papers o Trial registration: 1/6 papers o Two sets of trials with possibly duplicate data leading to retraction of a meta-analysis, other papers with identical text
34 Retraction by Heart raw data no longer available having been lost as a result of computer failure
35 Recommendations Sodium Intake
36 2010 Dietary Guidelines: Sodium Recommendation Reduce intake to less than 2300 mg/day Further reduce intake to 1500 mg/day for: Adults ages 51+ African Americans ages 2+ People ages 2+ with high blood pressure, diabetes, or chronic kidney disease
37 Conclusion Elevated blood pressure is the leading cause of preventable death worldwide No (minimal) debate about lowering sodium intake to 2,300 mg/d Major methodological issues limit the usefulness of recent studies as a basis for guiding policy, much less reversing recommendations
38 Bottom Line (Unchanged) The estimated benefits of sodium reduction are substantial and warrant major public health efforts to reduce salt intake Prevailing recommendations align with best evidence and do not warrant any change in policy
Health Benefits of Lowering Sodium Intake in the US
Health Benefits of Lowering Sodium Intake in the US Lawrence J Appel, MD, MPH Professor of Medicine, Epidemiology and International Health (Human Nutrition) Director, Welch Center for Prevention, Epidemiology
Sodium and Health: Evidence, Policy, Reality
Sodium and Health: Evidence, Policy, Reality Cheryl A. M. Anderson, PhD, MPH, MS University of California San Diego Department of Family Medicine and Public Health Email: c1anderson@ucsd.edu Sodium Intake
Disclaimer for sharing or use of any of this presentation
Disclaimer for sharing or use of any of this presentation If you share or use this presentation, any parts of it, or any of the info in it is used, please ensure you always credit the Ohio Cardiovascular
The Need for Balance in Evaluating the Evidence on Na and CVD
The Need for Balance in Evaluating the Evidence on Na and CVD Salim Yusuf Professor of Medicine, McMaster University Executive Director, Population Health Research Institute Vice-President Research, Hamilton
Why you should take the latest sodium study with a huge grain of salt
Harvard School of Public Health The Nutrition Source Flawed Science on Sodium from JAMA Why you should take the latest sodium study with a huge grain of salt A new study would have you believe that low-salt
Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N
NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N OBJECTIVES List controversial points from the current Dietary Guidelines for Americans (DGA). Recognize the policy
What s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
Salt: How much less should we eat for health? Understanding the recent IOM report
Salt: How much less should we eat for health? Understanding the recent IOM report We should all eat less salt but how much less? 1500 milligrams a day has been recommended as a target but the US Institute
Hypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
The Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
Project Summary: Draft Proposal Continued RESULTS. on the DASH Diet and 30 of the 40 original subjects on the Pro-DASH Diet.
Project Summary: Draft Proposal Continued RESULTS Subjects The HNFE 3034 Spring 2013 semester s research study included 34 of the 38 original subjects on the DASH Diet and 30 of the 40 original subjects
In almost every country that has established guidelines for
AHA Presidential Advisory Sodium, Blood Pressure, and Cardiovascular Disease Further Evidence Supporting the American Heart Association Sodium Reduction Recommendations Paul K. Whelton, MB, MD, MSc, FAHA,
Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand
Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Presentation outline Strengths & weaknesses of short-term risk approach Strengths &
Controversies in Preventative Cardiology
Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence
Reduced Carbohydrate Intake May Lower Cardiovascular Risk CME
To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/516977 This activity is supported by funding from WebMD. Reduced
Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3)
Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3) Χάρης Γράσσος MD,FESC,PhD,EHS Διευθυντής Καρδιολόγος Γ.Ν.Α ΚΑΤ Visiting Professor University of Bolton U.K New England
HYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
Salt reduction - benefits beyond blood pressure
Salt reduction - benefits beyond blood pressure Jennifer Keogh Associate Professor Sansom Institute for Health Research University of South Australia Intersalt study 1 Epidemiological study of electrolyte
John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Ho Chi Minh City, Vietnam August 7, 2014 JBS 2 Risk Guidelines (2005) Based
10/8/2015. MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH. None
MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH None 1 Objectives Why the need for change in the guidelines? What is the potential impact of these guidelines? Where do we go from here?
MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
Cardiovascular Risk Assessment and Management Making a Difference
Cardiovascular Risk Assessment and Management Making a Difference Norman Sharpe March 2014 Numbers and age-standardised mortality rates from all causes, by sex, 1950 2010 Death rates halved Life expectancy
Sodium and Potassium Intake and Cardiovascular and Bone Health:
Sodium and Potassium Intake and Cardiovascular and Bone Health: How Important is the Ratio? Connie M. Weaver Nutrition Science Purdue University Disclosures Boards/Scientific Advisory Committees ILSI Showalter
Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
Heart Disease Genesis
Heart Disease Genesis The Ultimate Lecture on CAD origins Petr Polasek MD FRCPC FACC Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
Diabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
SUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Supplemental Table 1. Distribution of Participants Characteristics by Treatment Group at Baseline - The Vitamin D and calcium (CaD) Trial of the Women s Health Initiative (WHI) Study,
Vascular Diseases. Overview: Selected Slides
Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates
Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
Update in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
Using the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
Hypertension Update Background
Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison
Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
Tiny Jaarsma Linköping University No conflict of interest
Detrimental effects of sodium in heart failure - Tiny Jaarsma Linköping University No conflict of interest Sodium restriction in Heart Failure Why? Prevention of heart failure Blood pressure treatment
Hypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
Primary Physiological
Appendix Table 3. Primary outcomes and effect sizes for trials included in review. Trial Behavior Outcome Effect size Group difference in original units Primary Physiological ACT 22, a Be Fit, Be Well
Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
Blood pressure and urinary sodium in men and women: the Norfolk Cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk) 1 3
Blood pressure and urinary sodium in men and women: the Norfolk Cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk) 1 3 Kay-Tee Khaw, Sheila Bingham, Ailsa Welch, Robert Luben,
Hypertension Update. Aaron J. Friedberg, MD
Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline
The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
The Gender Divide Women, Men and Heart Disease February 2017
The Gender Divide Women, Men and Heart Disease February 2017 Nandita S. Scott, MD FACC Co-Director MGH Heart Center Corrigan Women s Heart Health Program Massachusetts General Hospital Heart Disease For
Mesures non médicamenteuses pour prévenir et traiter une hypertension artérielle. JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège
Mesures non médicamenteuses pour prévenir et traiter une hypertension artérielle JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège Disclosure No competing interest to declare about this
International model for prevention of chronic disease: Finland experience
International model for prevention of chronic disease: Finland experience Erkki Vartiainen, MD, Professor, Assistant Director General 06/12/2011 Erkki Vartiainen 1 2 Start of the North Karelia project
Preventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
Sodium: Too much, too little or just right?
NUTRI-BITES Webinar Series Sodium: Too much, too little or just right? November 6, 2014 Presenter: Robert P. Heaney, MD John A. Creighton University Professor/Professor of Medicine Creighton University
Fructose, Uric Acid and Hypertension in Children and Adolescents
Fructose, Uric Acid and Hypertension in Children and Adolescents Daniel I. Feig, MD, PhD, MS Director, Division of Nephrology Department of Pediatrics University of Alabama, Birmingham Topics for Discussion
Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
Placebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease
Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease Simin Liu, MD, ScD Professor of Epidemiology and Medicine Director, Center for Global Cardiometabolic Health Brown
Jared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
Know Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
Economically efficient approaches to address chronic disease in developing countries
Economically efficient approaches to address chronic disease in developing countries Thomas A. Gaziano MD MSc Division of Cardiovascular Medicine Brigham & Women s Hospital Harvard Medical School Center
Interventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
Systolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
Fatty acids and cardiovascular health: current evidence and next steps
Fatty acids and cardiovascular health: current evidence and next steps Emanuele Di Angelantonio, MD, PhD Department of Public Health and Primary Care NICE guidelines on fatty acids Eliminate the use of
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:
Part 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives.
Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes Stephen D. Sisson MD Objectives To review dietary recommendations in the following conditions: Obesity Hypertension Diabetes
Implementing Type 2 Diabetes Prevention Programmes
Implementing Type 2 Diabetes Prevention Programmes Jaakko Tuomilehto Department of Public Health University of Helsinki Helsinki, Finland FIN-D2D Survey 2004 Prevalence of previously diagnosed and screen-detected
Adverse Effects: Consideration of Chronic Disease Endpoints and Beyond Amanda MacFarlane, PhD. Nutrition Research Division, Health Canada, Ottawa, ON
Adverse Effects: Consideration of Chronic Disease Endpoints and Beyond Amanda MacFarlane, PhD Nutrition Research Division, Health Canada, Ottawa, ON Adverse effects can be described as: Biochemical and
Blood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
Primary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
Weintraub, W et al NEJM March Khot, UN et al, JAMA 2003
Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine
Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
The Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
Folate, vitamin B 6, and vitamin B 12 are cofactors in
Research Letters Dietary Folate and Vitamin B 6 and B 12 Intake in Relation to Mortality From Cardiovascular Diseases Japan Collaborative Cohort Study Renzhe Cui, MD; Hiroyasu Iso, MD; Chigusa Date, MD;
Intermediate Methods in Epidemiology Exercise No. 4 - Passive smoking and atherosclerosis
Intermediate Methods in Epidemiology 2008 Exercise No. 4 - Passive smoking and atherosclerosis The purpose of this exercise is to allow students to recapitulate issues discussed throughout the course which
No relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
Adolescent Hypertension Roles of obesity and hyperuricemia. Daniel Landau, MD Pediatrics, Soroka University Medical Center
Adolescent Hypertension Roles of obesity and hyperuricemia Daniel Landau, MD Pediatrics, Soroka University Medical Center Blood Pressure Tables BP standards based on sex, age, and height provide a precise
Diabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
Hypertension, Hyperlipidemia and Obesity. Mi-CCSI
Hypertension, Hyperlipidemia and Obesity Mi-CCSI Objectives Review the prevalence of hypertension, hyperlipidemia and obesity Correlation of the 3 conditions Discuss why it is important to treat these
NOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet
NOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet FASTING 16 hours a day EXCERCISE 150 min a week DIET Low carb NOSM Northern Research Conference, Kenora, 2018 R Minty, T O Driscoll, L Kelly,
None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture
Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
Clinical and Public Health Progress Each Contributed About Half to the 50% Reduction in Heart Disease Deaths, US,
The Beat Goes On Kim La Croix, MPH, RD Nutrition Coordinator/Public Health Nutritionist Public Health Division Center for Prevention & Health Promotion Health Promotion Chronic Disease Prevention Objectives
Hypertension in the very old. Objectives: Clinical Perspective
Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical
Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C
Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C Thomas P. Bersot, M.D., Ph.D. Gladstone Institute of Cardiovascular Disease University
Healthy Fats & Fatty Acids Current Dietary Recommendations and Popular Opinions
Healthy Fats & Fatty Acids Current Dietary Recommendations and Popular Opinions Presentation 1 of 2 Penny M. Kris-Etherton PhD RD FAHA FNLA FASN CLS Department of Nutritional Sciences Penn State University
Inflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
Cardiovascular Outcome
Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children: Cardiovascular Outcome D R. J E F F R E Y G O L D B E R G E R U
Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women
Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women (Lancet. 2017 Mar 25;389(10075):1229-1237) 1 Silvia STRINGHINI Senior
Kidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
Role of Minerals in Hypertension
Role of Minerals in Hypertension Lecture objectives By the end of the lecture students will be able to Define primary and secondary hypertention and their risk factors. Relate role of minerals with hypertention.
Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
Page down (pdf converstion error)
1 of 6 2/10/2005 7:57 PM Weekly August6, 1999 / 48(30);649-656 2 of 6 2/10/2005 7:57 PM Achievements in Public Health, 1900-1999: Decline in Deaths from Heart Disease and Stroke -- United States, 1900-1999
Reducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors